Global epidemiology, genotype distribution and coinfection rate of Human Aichi virus: A systematic review
Abstract
BACKGROUND
Acute gastroenteritis is a major health concern for all age groups and accounts for more than 2.5 million deaths annually in children under five years old. Human Aichi virus causes acute gastroenteritis and is associated with foodborne outbreaks. Little is known about its pathogenicity, evolution, and geographical distribution.
OBJECTIVE
This study aimed to describe the global seroprevalence of AiV-1 and its genotype distribution, track outbreaks, and estimate co-infection rates with other viral gastroenteritis.
METHODS
A comprehensive systematic search of the epidemiological aspects of AiV-1 was conducted using peer-reviewed English original articles indexed in several scientific database libraries since its first detection in Japan until October 2022. A total of 55 published studies were included in the final analysis based on the inclusion criteria.
RESULT
The global prevalence of AiV-1 was 1.45 %. To date, nine AiV-1 outbreaks were reported following the first oyster-associated outbreak in Japan between 1987 and 1991. AiV-1 genotype A has a worldwide distribution, whereas genotypes B and C have a pattern of geo-localization. The gradual and significant increase of AiV-1 seroprevalence with age was reported in all studies. The most predominant viruses causing viral coinfection among AiV-1-infected patients were Norovirus (36.55 %), Rotavirus (18.91 %), and Sapovirus (15.13 %). Coinfections with Norovirus (p-value 0.003), Rotavirus (p = 0.007), and Human…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.